scholarly journals Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas

2014 ◽  
Vol 4 ◽  
Author(s):  
Ibrahim Qaddoumi ◽  
Mehmet Kocak ◽  
Atmaram S. Pai Panandiker ◽  
Gregory T. Armstrong ◽  
Cynthia Wetmore ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
High Grade ◽  
Newly Diagnosed ◽  
High Grade Gliomas

Phase II trial of topotecan (T) as a continuous intravenous infusion in patients (PTS) with high grade gliomas

1997 ◽  
Vol 33 ◽  
pp. S203
Author(s):  
A. Kyritsis ◽  
E.S. Newlands ◽  
C.S. Brock ◽  
K. Jaeckle ◽  
V. Levin ◽  
...  
Keyword(s):  
Phase Ii ◽  
Intravenous Infusion ◽  
Phase Ii Trial ◽  
High Grade ◽  
Continuous Intravenous Infusion ◽  
High Grade Gliomas

Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 1522-1522 ◽  
Author(s):  
U. Bode ◽  
S. Buchen ◽  
G. Janssen ◽  
T. Reinhard ◽  
M. Warmuth-Metz ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Trial ◽  
Phase Iii ◽  
High Grade ◽  
Consolidation Therapy ◽  
Pontine Glioma ◽  
Multicentre Phase ◽  
High Grade Gliomas

1522 Background: Children and adolescents suffering from high grade gliomas (HGG) have a poor prognosis when they relapse during or after primary treatment. Thus novel therapeutic approaches as the inhibition of growth-signalling pathways are needed. This multicentre phase II trial was designed to explore the feasibility and efficacy of the h-R3 monoclonal anti-EGFR antibody (Nimotuzumab) in the treatment of these patients. Methods: Pediatric patients with glioblastoma multiforme, anaplastic astrocytoma or intrinsic pontine glioma (PG) with radiologically proven progressive disease following primary or relapse treatment were eligible to the study. The treatment consisted of an induction therapy including a weekly short infusion of 150 mg/m2 Nimotuzumab for six weeks, and in case of non-PD a subsequent consolidation therapy of four infusions in a three week interval. The response was documented by MRI in week 8 and 21. Results: Between June 2004 and August 2005 34 patients aged 5.0 to 17.4 years (median 10.9 years) were enrolled in this study. According to RECIST 12 out of 34 patients showed response (PR n=1, SD n=11) in the MRI of week 8 after the induction therapy with a median change in the largest diameter of the index lesion of −5% (−39 to +16%) accompanied by clinical deterioration in four and markedly clinical improvement in two patients. Surprisingly, 9 PR/SD were seen in the 14 patients with PG. Eight patients continued with the consolidation therapy. So far 5 out of 8 Patients are evaluable for response after consolidation therapy and showed three PR, one SD and one PD in week 21. Eight patients with consolidation therapy are free of progression for a median of 7.5 months (1.2–13.2 months). No severe side effects related to the study medication were observed. Conclusions: These data suggest that the repeated application of Nimotuzumab is well tolerated and safe. It has cytotoxic efficacy in heavily pre-treated relapsed HGG, especially in intrinsic pontine glioma. A phase III study for patients with newly diagnosed PG is warranted. [Table: see text]

Prospective phase II trial for recurrent high-grade gliomas with capacitive coupled low radiofrequency (LRF) hyperthermia

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 2047-2047 ◽  
Author(s):  
E. D. Hager ◽  
H. Sahinbas ◽  
D. H. Groenemeyer ◽  
F. Migeod
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
High Grade ◽  
Prospective Phase ◽  
High Grade Gliomas

Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas

2010 ◽  
Vol 102 (2) ◽  
pp. 317-321 ◽  
Author(s):  
Manmeet S. Ahluwalia ◽  
Carol Patton ◽  
Glen Stevens ◽  
Tanya Tekautz ◽  
Lilyana Angelov ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
High Grade ◽  
High Grade Gliomas

Phase II Trial with BCNU plus α-Interferon in Patients with Recurrent High-Grade Gliomas

1997 ◽  
Vol 20 (4) ◽  
pp. 364-367 ◽  
Author(s):  
Alba Ariela Brandes ◽  
Elvira Scelzi ◽  
Paolo Zampieri ◽  
Alberto Rigon ◽  
Antonino Rotilio ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
High Grade ◽  
High Grade Gliomas

scholarly journals Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

2020 ◽  
Vol 26 (8) ◽  
pp. 1856-1865 ◽  
Author(s):  
Daniel Rodriguez Gutierrez ◽  
Chris Jones ◽  
Pascale Varlet ◽  
Alan Mackay ◽  
Daniel Warren ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
High Grade Glioma ◽  
High Grade ◽  
Radiological Evaluation ◽  
Newly Diagnosed ◽  
Pediatric High Grade Glioma

A phase II trial of LY317615 in patients with recurrent high grade gliomas

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 1511-1511 ◽  
Author(s):  
H. A. Fine ◽  
L. Kim ◽  
C. Royce ◽  
S. Mitchell ◽  
J. P. Duic ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
High Grade ◽  
High Grade Gliomas
Sign in / Sign up

Export Citation Format

Share Document